What is Phagenyx?
Phagenyx specializes in the Phagenyx System, a neurostimulation device engineered to enhance swallowing safety and efficiency for patients experiencing post-stroke dysphagia. By employing pharyngeal electrical stimulation, the system aims to restore the brain's natural control over the swallowing reflex, thereby accelerating patient recovery and reducing the duration of hospital stays. The company targets healthcare providers, focusing on improving patient outcomes through evidence-based interventions and extensive clinical research, positioning itself as a transformative force in dysphagia care.
How much funding has Phagenyx raised?
Phagenyx has raised a total of $62.5M across 4 funding rounds:
Series A
$2.3M
Grant
$1.1M
Series B
$17M
Series D
$42M
Series A (2010): $2.3M with participation from Undisclosed
Grant (2012): $1.2M led by Wellcome Trust
Series B (2013): $17M supported by Inventages
Series D (2024): $42M featuring Northern Gritstone, Sectoral Asset Management, British Patient Capital, and EQT Group
Key Investors in Phagenyx
Northern Gritstone
Northern Gritstone is an investment company focused on supporting science and technology businesses in the North of England, aiming for profit with purpose by combining strong investor returns with positive societal impacts.
Sectoral Asset Management
Sectoral Asset Management is an investment advisor specializing in global healthcare equities, offering various public and private equity strategies with a strong focus on biotech.
British Patient Capital
British Patient Capital, part of the British Business Bank, provides financial support to UK businesses, including equity finance, to help them grow and expand.
What's next for Phagenyx?
The recent major strategic investment signifies a pivotal moment for Phagenyx, likely enabling the company to scale its operations, expand its market reach, and further invest in research and development. This substantial backing suggests a transition into a growth or expansion phase, where the focus will be on commercializing its neurostimulation technology more broadly and solidifying its position in the dysphagia treatment market. Future developments may include broader clinical adoption, potential international expansion, and continued refinement of the Phagenyx System based on real-world clinical data.
See full Phagenyx company page
